Back to Search
Start Over
Preemptive inotuzumab ozogamicin eradicated measurable residual disease in Ph-negative acute lymphoblastic leukemia relapsed post CD19 CART therapy.
- Source :
-
Clinical case reports [Clin Case Rep] 2023 Dec 09; Vol. 11 (12), pp. e8289. Date of Electronic Publication: 2023 Dec 09 (Print Publication: 2023). - Publication Year :
- 2023
-
Abstract
- There are no reports of application of inotuzumab ozogamicin (InO) for the treatment of MRD in r/r B-ALL. We firstly report the efficacy of InO for a patient experienced morphological relapse after HSCT and molecular relapse after CART therapy.<br />Competing Interests: The authors declare no competing interests.<br /> (© 2023 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.)
Details
- Language :
- English
- ISSN :
- 2050-0904
- Volume :
- 11
- Issue :
- 12
- Database :
- MEDLINE
- Journal :
- Clinical case reports
- Publication Type :
- Report
- Accession number :
- 38084356
- Full Text :
- https://doi.org/10.1002/ccr3.8289